Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the effect of food on the absorption of the drug as well as safety and tolerability of the novel 30 mg tablet (administered as 120 mg dose) in adults suffering from chronic Chagas' disease when administered after a high-fat / high-calorie test meal (American breakfast) compared to a fasting state. This study is required as part of the clinical development of an age appropriate pediatric oral dosage form for the treatment of Chagas' disease in endemic countries according to the recommendations provided by current international guidelines (EMA Guideline on Clinical Development of Medicinal Products, EMA Note for Guidance on Oral Dosage Forms).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02606864
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date December 2015
Completion date August 2016

See also
  Status Clinical Trial Phase
Completed NCT01162967 - Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Phase 2
Completed NCT00023556 - Genetic Architecture of Heart Disease in Rural Brazil N/A
Active, not recruiting NCT04024163 - Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease Phase 3
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Completed NCT03892213 - Pharmacokinetic Drug-Drug Interaction Study Phase 1
Recruiting NCT00875173 - Selenium Treatment and Chagasic Cardiopathy (STCC) Phase 3
Recruiting NCT03704181 - Colchicine for Patients With Chagas´ Disease( B1 Stage) Phase 2
Active, not recruiting NCT03378661 - BENDITA BEnznidazole New Doses Improved Treatment and Associations Phase 2
Completed NCT01927224 - Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Phase 1
Completed NCT01006486 - Outcomes of an Anticoagulation Clinic in an University Hospital Phase 4
Completed NCT00123916 - BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Phase 3
Completed NCT02516293 - Cardiac Rehabilitation in Chagas Heart Failure Phase 2/Phase 3
Completed NCT02517632 - Physical Exercise Program in Chronic Chagas Heart Disease Phase 3
Recruiting NCT02099903 - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease N/A
Completed NCT01874795 - Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure N/A
Completed NCT01006473 - Exercise Training in Chagas Cardiomyopathy Phase 4
Completed NCT02386358 - Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Phase 3
Not yet recruiting NCT05477953 - An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
Completed NCT02346123 - Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy N/A
Recruiting NCT02295215 - Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction N/A